...
首页> 外文期刊>Brain research >Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease.
【24h】

Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease.

机译:载脂蛋白D基因多态性与散发性阿尔茨海默病的关系。

获取原文
获取原文并翻译 | 示例

摘要

Apolipoprotein D (apoD) is a lipoprotein-associated glycoprotein that is increased in the hippocampus and cerebrospinal fluid of patients with Alzheimer's disease (AD), which implies that apoD might be involved in the pathogenesis of AD. We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing techniques to screen all exons (1-5) and the flanking exon-intron boundaries of the apoD gene (APOD). Thirty subjects [15 sporadic AD (SAD) patients and 15 controls] were randomly selected and tested for APOD variations by direct sequencing. Two APOD polymorphisms (rs5952T/C and rs1568566C/T) were detected. We further investigated APOD polymorphisms in 256 SAD patients and 294 healthy subjects from a North Chinese population to investigate whether they affect the risk of SAD. Logistic analysis revealed that both rs5952 C and rs1568566 T alleles increase the risk of SAD [rs5952, adjusted odds ratio (OR) 1.817, 95% confidence interval (CI) 1.237-2.669, P = 0.002; rs1568566, adjusted OR 1.563, 95% CI 1.060-2.306, P = 0.024). The rs5952T-rs1568566C haplotype showed lower risk of SAD (OR 0.421, 95% CI 0.305-0.583, P = 0.000). Case-control analysis revealed that the rs5952T-rs1568566C haplotype could serve as a novel defendant factor against SAD. APOD polymorphisms might play an important role in modifying SAD risk in some way.
机译:载脂蛋白D(Apod)是脂蛋白相关的糖蛋白,其在阿尔茨海默病(AD)患者的海马和脑脊液中增加,这意味着Apod可能参与广告的发病机制。我们使用聚合酶链反应限制性片段长度多态性(PCR-RFLP)和DNA测序技术,以筛选所有外显子(1-5)和Apod基因(Apod)的侧翼外显子界。三十个受试者[15次孢子症AD(悲伤)患者和15例对照]随机选择并测试Apod变化通过直接测序。检测到两个Apod多态性(RS5952T / C和RS156856C / T)。我们进一步研究了256名悲伤患者的Apod多态性,并从北方北方人口中进行了294名健康科目,调查它们是否影响悲伤的风险。逻辑分析显示,RS5952 C和RS1568566 T等位基因增加了悲伤的风险[RS5952,调整后的差距(或)1.817,95%置信区间(CI)1.237-2.669,P = 0.002; RS1568566,调整或1.563,95%CI 1.060-2.306,P = 0.024)。 RS5952T-RS1568566C单倍型显示出悲伤的风险较低(或0.421,95%CI 0.305-0.583,P = 0.000)。案例控制分析显示,RS5952T-RS1568566C单倍型可以作为悲伤的新被告因子。 Apod多态性可能在以某种方式修改悲伤风险方面发挥着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号